A landmark clinical trial led by researchers at UCL has revealed that hundreds of thousands of low-risk thyroid cancer patients worldwide may no longer need radioactive iodine treatment after surgery. Published in The Lancet, the study found that omitting this therapy did not compromise recovery, allowing patients to avoid side effects and isolation while returning to normal life faster.
The Iodine or Not (IoN) trial, funded by Cancer Research UK, involved 504 patients aged 17-80 from 33 UK cancer centers. All participants had low-risk thyroid cancer, with half randomly assigned to receive radioactive iodine post-surgery and the other half receiving surgery alone. After five years, 98% of patients who skipped radiation remained cancer-free, compared to 96% in the treatment group, a difference researchers attributed to chance rather than clinical significance.
Thyroid cancer affects approximately 820,000 people globally each year, disproportionately impacting women and younger individuals, many of whom are parents. Radioactive iodine therapy traditionally requires hospitalization in isolation for 1–3 days, followed by prolonged safety precautions to protect others, especially children, from radiation exposure.
Professor Allan Hackshaw of UCL Cancer Institute emphasized the trial’s implications: “This treatment represents over-treatment for low-risk patients. Avoiding it improves quality of life, enabling faster reunions with families.” Dr. Ujjal Mallick, the trial’s chief investigator, added that skipping radiation eliminates risks like dry mouth, salivary gland damage, and rare secondary cancers.
- Dr. Kate Newbold (The Royal Marsden NHS Foundation Trust): “IoN demonstrates the UK’s ability to lead practice-changing cancer trials with global impact.”
- Kate Farnell (Butterfly Thyroid Cancer Trust): “Patients often describe isolation as the hardest part of their journey. This trial spares them that burden.”
The findings could immediately influence clinical guidelines, benefiting an estimated 2,500 UK and 400,000 global patients annually. Beyond improving lives, the reduced need for radiation therapy may lower healthcare costs and ease hospital demands. The study underscores the importance of tailoring treatments to individual risk levels in cancer care.
Add comment